AR068439A1 - Derivado de 6-pirimidinil-pirimid-2-ona - Google Patents

Derivado de 6-pirimidinil-pirimid-2-ona

Info

Publication number
AR068439A1
AR068439A1 ARP080103982A ARP080103982A AR068439A1 AR 068439 A1 AR068439 A1 AR 068439A1 AR P080103982 A ARP080103982 A AR P080103982A AR P080103982 A ARP080103982 A AR P080103982A AR 068439 A1 AR068439 A1 AR 068439A1
Authority
AR
Argentina
Prior art keywords
pirimid
pirimidinil
ona
derived
disease
Prior art date
Application number
ARP080103982A
Other languages
English (en)
Inventor
Jesus Benavides
Jeremy Pratt
Pascal Barneoud
Kazutoshi Watanabe
Kenji Fukunaga
Original Assignee
Mitsubishi Tanabe Pharma Corp
Dupuis Laurent
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP08290028A external-priority patent/EP2078717A1/en
Application filed by Mitsubishi Tanabe Pharma Corp, Dupuis Laurent filed Critical Mitsubishi Tanabe Pharma Corp
Publication of AR068439A1 publication Critical patent/AR068439A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un compuesto representado por la formula (1) o una sal farmacéuticamente aceptable de él: que se usa para el tratamiento preventivo y/o terapéutico de una enfermedad provocada por la actividad anormal de la tau proteína cinasa 1 tal como enfermedades neurodegenerativas (por ejemplo, la enfermedad de Alzheimer).
ARP080103982A 2007-09-14 2008-09-12 Derivado de 6-pirimidinil-pirimid-2-ona AR068439A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2007269485 2007-09-14
JP2007275713 2007-09-25
EP08290028A EP2078717A1 (en) 2008-01-11 2008-01-11 6-Pyrimidinyl-pyrimid-2-one derivative

Publications (1)

Publication Number Publication Date
AR068439A1 true AR068439A1 (es) 2009-11-18

Family

ID=39874051

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080103982A AR068439A1 (es) 2007-09-14 2008-09-12 Derivado de 6-pirimidinil-pirimid-2-ona

Country Status (15)

Country Link
US (2) US8198437B2 (es)
EP (1) EP2193129B1 (es)
JP (1) JP5249320B2 (es)
KR (1) KR20100074182A (es)
CN (1) CN101883770A (es)
AR (1) AR068439A1 (es)
AU (1) AU2008297817A1 (es)
BR (1) BRPI0816705A2 (es)
CA (1) CA2698819A1 (es)
EA (1) EA201070367A1 (es)
MX (1) MX2010002765A (es)
NZ (1) NZ584277A (es)
TW (1) TW200927134A (es)
WO (1) WO2009035162A1 (es)
ZA (1) ZA201002213B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200813015A (en) * 2006-03-15 2008-03-16 Mitsubishi Pharma Corp 2-(cyclic amino)-pyrimidone derivatives
MX2010002765A (es) 2007-09-14 2010-05-19 Mitsubishi Tanabe Pharma Corp Derivado de 6-pirimidinil-pirimid-4-ona.
TW201043618A (en) 2009-03-10 2010-12-16 Sanofi Aventis Intermediate compound for synthesizing pharmaceutical agent and production method thereof
EP2464632A1 (en) 2009-08-13 2012-06-20 Mitsubishi Tanabe Pharma Corporation Pyrimidone derivatives used as tau protein kinase 1 inhibitors
WO2011019089A1 (en) * 2009-08-13 2011-02-17 Mitsubishi Tanabe Pharma Corporation Pyrimidone derivatives used as tau protein kinase 1 inhibitors
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP3453706A1 (en) 2017-09-08 2019-03-13 Basf Se Pesticidal imidazole compounds

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2116460A1 (en) 1993-03-02 1994-09-03 Mitsubishi Chemical Corporation Preventive or therapeutic agents for alzheimer's disease, a screening method of alzheimer's disease and tau-protein kinase i originated from human being
MXPA04002662A (es) * 2001-09-21 2004-11-22 Sanofi Aventis Derivados de 3-substituida-4-pirimidona.
AR036604A1 (es) * 2001-09-21 2004-09-22 Mitsubishi Pharma Corp Derivados de 4-pirimidona 3-sustituida
TWI357408B (en) * 2003-03-26 2012-02-01 Mitsubishi Tanabe Pharma Corp 3-substituted-4-pyrimidone derivatives
TW200621760A (en) * 2004-09-09 2006-07-01 Mitsubishi Pharma Corp 2-morpholino-4-pyrimidone compound
ZA200703383B (en) 2004-09-29 2009-05-27 Mitsubishi Pharma Corp 6-(pyridinyl)-4-pyrimidone derivates as tau protein kinase 1 inhibitors
TW200740779A (en) 2005-07-22 2007-11-01 Mitsubishi Pharma Corp Intermediate compound for synthesizing pharmaceutical agent and production method thereof
TW200813015A (en) 2006-03-15 2008-03-16 Mitsubishi Pharma Corp 2-(cyclic amino)-pyrimidone derivatives
AR064660A1 (es) * 2006-12-26 2009-04-15 Mitsubishi Tanabe Pharma Corp Derivados de pirimidinona 6-heterociclica 2-sustituida, medicamentos que los contienen y usos para prevenir y/o tratar enfermedades neurodegenerativas entre otras
MX2010002765A (es) 2007-09-14 2010-05-19 Mitsubishi Tanabe Pharma Corp Derivado de 6-pirimidinil-pirimid-4-ona.
AR076014A1 (es) 2009-04-02 2011-05-11 Sanofi Aventis Derivados de 3- (1,4) oxazepan -4-pirimidona

Also Published As

Publication number Publication date
EP2193129A1 (en) 2010-06-09
WO2009035162A1 (en) 2009-03-19
TW200927134A (en) 2009-07-01
KR20100074182A (ko) 2010-07-01
US20110021773A1 (en) 2011-01-27
AU2008297817A1 (en) 2009-03-19
CA2698819A1 (en) 2009-03-19
EP2193129B1 (en) 2012-10-24
NZ584277A (en) 2011-11-25
JP2010538969A (ja) 2010-12-16
US8198437B2 (en) 2012-06-12
US8518939B2 (en) 2013-08-27
EA201070367A1 (ru) 2010-08-30
MX2010002765A (es) 2010-05-19
BRPI0816705A2 (pt) 2015-03-17
JP5249320B2 (ja) 2013-07-31
CN101883770A (zh) 2010-11-10
ZA201002213B (en) 2011-06-29
US20120252812A1 (en) 2012-10-04

Similar Documents

Publication Publication Date Title
AR068438A1 (es) Derivado de 6-pirimidinil-pirimid-2-ona
DOP2019000187A (es) Compuestos de 5-metil-1,2,4-oxadiazol-3-ilo
AR111693A1 (es) Compuestos de 5-metil-1,3,4-oxadiazol-2-ilo con actividad inhibitoria de oga
AR068439A1 (es) Derivado de 6-pirimidinil-pirimid-2-ona
EA201891703A1 (ru) Соединения бензопиразола и их аналоги
SV2006002055A (es) Compuestos de imidazol para el tratamiento de trastornos neurodegenerativos ref. pc32054a
TN2015000391A1 (en) Compounds and compositions for the treatment of parasitic diseases
MX2020010151A (es) Analogos de piridazina 1,4-disustituida y metodos para el tratamiento de condiciones relacionadas con la deficiencia de smn.
BRPI0513433A (pt) derivados de hidantoìna para o tratamento de distúrbios inflamatórios
NO20090755L (no) Amino-imidazoloner og deres anvendelse som et medikament for behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerering og demens
EA200901373A1 (ru) Аминогетероциклические соединения
CO6670589A2 (es) Compuestos para reducir la producción de beta-amiloide
CL2007002288A1 (es) Compuestos derivados de imidazol-amina condensados, inhibidores de la beta-secretasa; proceso de preparacion; composicion farmaceutica, util para el tratamiento, prevencion o mejoramiento de enfermedades tales como enfermedad de alzheimer, deterioro
AR059948A1 (es) Formas farmaceuticas y metodos de tratamiento que usan un inhibidor de la tirosinacinasa
EA200900152A1 (ru) Ингибиторы пирролотриазинкиназы
NO20090166L (no) Amino-imidazoloner og deres anvendelse som et medikament for behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerering og demens
BRPI0515851A (pt) composto de pirimidona
EA201391485A1 (ru) Способы и композиции для лечения нейродегенеративных заболеваний
UY30377A1 (es) Inhibidores triciclicos fusionados de sulfonamida de gama-secretasa
EA201270359A1 (ru) Терапевтическое средство от расстройств настроения
UY28825A1 (es) Compuestos de sulfonamidas para el tratamiento de trastornos neurodegenerativos
CO2019013254A2 (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
HK1110211A1 (es)
UY31824A (es) Nuevos compuestos
CL2011000520A1 (es) Compuestos derivados de piperazina; uso para preparar un medicamento util para tratar la enfermedad de alzheimaer, un trastorno neurodegenerativo y amiloidosis; metodo de preparacion de compuestos.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal